Generic Name and Formulations:
Bacitracin 50,000units/vial; pwd for IM inj after reconstitution.
X-GEN Pharmaceuticals, Inc
Indications for BACIIM:
Susceptible infections due to staphylococci, including pneumonia and empyema in infants.
Give by IM inj into upper outer quadrant of buttocks. Infants: <2.5kg: 900units/kg per day in 2–3 divided doses; >2.5kg: 1,000units/kg per day in 2–3 divided doses.
Renal impairment. Monitor renal function before and daily during therapy; discontinue if renal toxicity occurs. Ensure adequate hydration.
Avoid other nephrotoxic drugs (eg, aminoglycosides, polymyxin B, colistin).
Nephrotoxicity (eg, albuminuria, azotemia, cylinduria), nausea, vomiting, rash, inj site pain.
Clinical Pain Advisor Articles
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Electroacupuncture May Help Reduce Opioid Use in Chronic Musculoskeletal Pain
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- Opioid Use Disorder Prevalence at Delivery on the Rise in the US, According to CDC
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Pharmacologically Induced Headache Accompanied by Dilated Cephalic Vessels
- IV Lidocaine May Be Safe, Efficacious for Pediatric Status Migraine
- Gray Matter Changes in Migraine Associated With Clinical Characteristics